Preclinical evaluation of safety and immunogenicity of a primary series intranasal covid-19 vaccine candidate (bbv154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with covaxin (bbv152)

HIGHLIGHTS

• who: Raju Sunagar and colleagues from the Health Canada, Canada University of Nebraska Medical Center have published the research: Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152), in the Journal: (JOURNAL)
• what: The authors report the safety and immunogenicity of BBV154 in laboratory animal models, i.e., mice, rats, hamsters and rabbits, following single or two dose IN administration, and heterologous prime-boost vaccination of BBV154 in combination with COVAXIN a whole virion inactivated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.